Imunon Reports Partial Results from Ongoing Non-human Primate Study
03 oct. 2022 08h00 HE
|
Imunon, Inc.
Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...